Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

NCT00521924 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Enrollment

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: infliximab
DRUG: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]